Five sites now opened in the pivotal Phase III clinical study SPARKLE for lead drug candidate Mangoral
(WorldNews Denmark)

Five sites now opened in the pivotal Phase III clinical study SPARKLE for lead drug candidate Mangoral Ascelia Pharma AB (publ) (ticker: ACE) today informed that there are a number of sites now open for enrolment of patients in both the US and Europe in the global pivotal Phase III clinical study SPARKLE with Mangoral[®]. Enrolment of the first patient is expected shortly. SPARKLE is a global multicenter and registration enabling study of Mangoral in up to 200 patients with severely reduced renal function and with known or suspected liver metastases. Ascelia Pharma expects top line results to be obtained by the end of 2020 or...